This observational study will evaluate the efficacy, safety and patient reported quality of life of palliative first-line Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) in patients with HER2-positive advanced breast cancer (metastatic or locally recurrent, inoperable) who relapsed after completed adjuvant Herceptin therapy. Additionally, information on selection criteria of breast cancer patients treated first-line with Perjeta, Herceptin and chemotherapy and their treatment duration will be collected and analyzed. Data will be collected from eligible patients for up to 20 months of treatment and 24 months of follow-up.
Study Type
OBSERVATIONAL
Enrollment
135
AGAPLESION Markus-Krankenhaus
Frankfurt, Germany
Median progression-free survival in routine clinical practice
Time frame: approximately 7.5 years
Dosage/schedule: Initiation/duration/modification/discontinuation of Perjeta administration
Time frame: approximately 7.5 years
Clinical/demographic patients characteristics at initiation of treatment
Time frame: approximately 7.5 years
Safety: Incidence of adverse events
Time frame: approximately 7.5 years
Patient reported outcome: Quality of life (FACT B questionnaire)
Time frame: approximately 7.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.